Health problems and confusing symptoms are not always easy to resolve. The human body usually does not reveal its deficiencies with superficial investigations. Lab tests to pinpoint the contributing causes of symptoms and disease are not commonly performed by conventional doctors.

The AMAS test is extremely sensitive; blood levels of this antibody rise early in the course of the vast majority of cancers of all types, regardless of location in the body. The test is especially useful when cancer is suspected but has not been confirmed by a biopsy.

The AMAS test also is useful in monitoring the treatment of malignancies. Levels typically return to normal within two to three months of successful treatment. Other biological markers in the blood are much less specific and are usually not elevated early in the course of disease or recurrence. Thus the AMAS test is an excellent way to screen for and detect cancer or recurrences, and to track treatment progress during treatment.

Conventional cancer treatment authorities are committed to a host of expensive and highly profitable diagnostic techniques (mammograms, MRIs, gastrointestinal series, etc.). Were it not for the intransigence of established authorities, the AMAS test undoubtedly would be much more widely used.

The AMAS test should be ordered and interpreted by a physician experienced with the test. False negatives and positives do occur.

• Female Hormone Profile - analyzes eleven saliva samples over a 28-day period for the levels of ß-estradiol, progesterone, and testosterone, providing clues about menstrual irregularities, infertility, endometriosis, breast cancer, and osteoporosis.
• Estrogen Metabolism Assessments - evaluate how estrogen is being processed in the body.
• Menopause Profile - examines three salivary samples over a 5-day period to determine levels of ß-estradiol, estriol, estrone, progesterone, and testosterone for women who are menopausal.
• Male Hormone Profile - analyzes four saliva samples over a 24-hour period for levels of testosterone, free testosterone, melatonin, and the estrogens.
• Comprehensive Thyroid Assessment - a comprehensive analysis of thyroid hormone secretion and metabolism, including central thyroid regulation and activity, peripheral thyroid function, and thyroid autoimmunity.
• Bone Resorption Assessment - a simple, direct urinary assay of pyridinium crosslinks and deoxypyridinoline, useful in identifying current rate of bone loss, lytic bone disease, and efficacy of bone support therapies.
• Glucose/Insulin Tolerance Test - employs a glucose challenge and blood samples over a four-hour period to assess the relationship of insulin and glucose.
• Adrenocortex Stress Profile - is a salivary assay of cortisol and DHEA, imbalances of which are associated with ailments ranging from obesity and menstrual disorders to immune deficiency and increased risk of cardiovascular disease.
• Comprehensive Melatonin Profile - analyzes three saliva samples for the secretion pattern of this important hormone.
  
• IGF-1 (Insulin-like Growth Factor-1 or Somatomedin C) - mediates many of the in vivo cell division and metabolic effects of growth hormone.

• Comprehensive Digestive Stool Analysis - evaluates digestion and absorption, bacterial balance and metabolism, parasite infection, yeast and immune status.
• Comprehensive Parasitology Profile - evaluates stool for presence of parasites and levels of beneficial flora, imbalanced flora, pathogenic bacteria, and yeast.
• Intestinal Permeability Assessment - analyzes urine for the clearance of two non-metabolized sugars, lactulose and mannitol. Identifies "leaky gut" and malabsorption.
• Heliobacter pylori Stool Antigen Test - an FDA-approved evaluation of H. pylori antigens shed directly in the stool. This test is useful for detecting the major causal bacterium associated with peptic ulcers, chronic gastritis, and increased risk of gastric cancer. This noninvasive test also provides a simple and sensitive clinical tool for monitoring eradication therapy.
• Total Element Clearance Profile (24 hr and Random/Timed) - measures urinary excretion of 9 nutrient elements and 20 toxic metals, including "classic" toxics such as lead, mercury, and arsenic, as well as newer technology toxics such as niobium and gadolinium.

• Cellular Energy Profile - evaluates fourteen organic acids that play a pivotal role in the generation of cell energy. Using a urine sample, the test can reveal metabolic distress associated with generalized pain and fatigue, which may arise in response to toxic exposure, nutrient imbalances, digestive dysfunction, and other causes
• Comprehensive Detoxification Profile - analyzes saliva, blood, and after- challenge doses of caffeine, aspirin, and acetaminophen in order to assess the Phase I and Phase II functional capacity of the liver to convert and clear toxic substances from the body. This profile includes markers for oxidative stress and important antioxidants.
• Oxidative Stress Analysis - identifies markers of hydroxyl radical activity, urine lipid peroxides, reduced glutathione, superoxide dismutase, and glutathione peroxidase, following a challenge dose of aspirin and acetaminophen.
• Comprehensive Cardiovascular Profile - analyzes blood for levels of HDL, LDL, lipid fractionation, total cholesterol, ratios, triglycerides, lipoprotein(a), homocysteine, fibrinogen, and high-sensitivity C-reactive protein. Includes Relative Risk Indices and Metabolic Syndrome Alerts.
• SpectraCell FIA 5000 - measures how micronutrients are actually functioning within your patients’ white blood cells. These tests allow nutritional assessment of your patients for a broad variety of clinical conditions including arthritis, cancer, cardiovascular risk, diabetes, various immunological disorders, metabolism disorders and micronutrient deficiencies.

• CardioGenomic™Profile - identifies genetic single nucleotide polymorphisms associated with increased risk of developing atherosclerosis, hypertension, and coronary artery disease. Risk factors include methylation defects, hyper-coagulation syndromes, cholesterol regulation defects, inflammation, general risk markers and cardio-protective markers.
• OsteoGenomic™Profile - identifies genetic single nucleotide polymorphisms associated with increased risk of developing osteopenia and osteoporosis. Risk factors include collagen synthesis, calcium metabolism, vitamin D3 activity, parathyroid hormone action, osteoclastic activity, and chronic inflammation.
• DetoxiGenomic™Profile - identifies genetic single nucleotide polymorphisms associated with increased risk of developing detoxification defects especially with increased exposure to xenobiotics and other toxins. Risk factors include altered cytochrome P-450 activity in phase 1 detoxification, impaired glutathione conjugation and acetylation in phase 2 reactions, altered catecholamine methylation and increased oxidative stress. Detoxification defects have been associated with increased risk for certain cancers, chronic fatigue, multiple chemical sensitivity, and alcoholism.
• ImmunoGenomic™Profile - identifies genetic single nucleotide polymorphisms associated with increased risk of developing defects in immune competence and surveillance. Risk factors include altered interleukin production and activity within the body and increased production of other cytokines like tissue necrosis factor alpha that may lead to conditions characterized by chronically up-regulated inflammatory response. Immunologic polymorphisms have been associated with increased risk of asthma, atopy, osteopenia, heart disease, and infectious diseases.

• Bioelectrical Impedance Analysis - considered one of the most exact and accessible methods of screening body fat. In conventional BIA, a person is weighed, then height, age and gender are entered in a computer. While the person is lying down, electrodes are attached to various parts of the body and a small electric signal is discharged that measures the impedance or resistance to muscle and fat. The more muscle, the lower the value, as the electricity passes easily through lean mass. A formula in the computer converts all of the data to indicate what percentage of the body is fat.
• Carotid Intima Media (CIMT) Testing - uses ultrasound to identify the early and intermediate stages of atherosclerosis, even if you show no outward signs or symptoms of the disease. Also measures the degree of inflammation in the arterial wall or the size of the plaque that may contribute to heart disease.